{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T13:57:41Z","timestamp":1713362261331},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s11739-022-02974-2","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T18:06:53Z","timestamp":1648231613000},"page":"1553-1554","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201cSGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series\u201d comment"],"prefix":"10.1007","volume":"17","author":[{"given":"Dimitrios","family":"Patoulias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"2974_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-022-02944-8","author":"M Zampieri","year":"2022","unstructured":"Zampieri M, Argir\u00f2 A, Allinovi M, Perfetto F, Cappelli F (2022) SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series. Intern Emerg Med. https:\/\/doi.org\/10.1007\/s11739-022-02944-8 (Published online ahead of print, 2022 Feb 8)","journal-title":"Intern Emerg Med"},{"key":"2974_CR2","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/brainsci11080980","volume":"11","author":"PM Ferraro","year":"2021","unstructured":"Ferraro PM, D\u2019Ambrosio V, Di Paolantonio A et al (2021) Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience. Brain Sci 11:980. https:\/\/doi.org\/10.3390\/brainsci11080980","journal-title":"Brain Sci"},{"key":"2974_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kws447","volume":"178","author":"M Nagata","year":"2013","unstructured":"Nagata M, Ninomiya T, Kiyohara Y et al (2013) Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan. Am J Epidemiol 178:1\u201311. https:\/\/doi.org\/10.1093\/aje\/kws447","journal-title":"Am J Epidemiol"},{"key":"2974_CR4","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000002050","volume":"37","author":"A Piperidou","year":"2019","unstructured":"Piperidou A, Sarafidis P, Boutou A et al (2019) The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 37:1334\u20131343. https:\/\/doi.org\/10.1097\/HJH.0000000000002050","journal-title":"J Hypertens"},{"key":"2974_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ et al (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8:582\u2013593. https:\/\/doi.org\/10.1016\/S2213-8587(20)30162-5 (published correction appears in Lancet Diabetes Endocrinol. 2020 Jun 25)","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-022-02974-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-022-02974-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T08:21:41Z","timestamp":1659601301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-022-02974-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2974"],"URL":"https:\/\/doi.org\/10.1007\/s11739-022-02974-2","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}